CHICAGO, June 22, 2011 /PRNewswire/ — Amended 13D for RepliGen Corporation was filed
with the SEC by Mr. Ronald L. Chez, a private investor.
Mr. Ronald L. Chez is the President of Ronald L. Chez, Inc., and
a private investor.
RepliGen Corporation is a biopharmaceutical company focused on
building an integrated company by developing and marketing
innovative drugs that deliver the benefits of protein therapies in
the fields of neurology and gastroenterology. RepliGen has a
core competency in the development and manufacturing of biologics
products, which is the basis for its bioprocessing business and
RepliGen has out-licensed certain biologics intellectual property,
which provide ongoing sources of revenue. Corporate
headquarters are located at 41 Seyon Street, Waltham, Massachusetts